A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Study Identifier
PCYC-0215
CT.gov Identifier
NCT00096837
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Blood Cancer - Multiple Myeloma
    • Study Drug
  • Motexafin Gadolinium Injection
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Inclusion Criteria: * Relapsed or Refractory Multiple Myeloma * ≥ 18 years old * Able to provide consent for participation * ECOG status 0-2 Lab values: * ANC ≥ 1,000/µL * WBC count ≥ 2.0/µL * Hemoglobin ≥ 8.0 g/dL * Platelet count ≥ 50,000/µL * AST and ALT ≤ 2 x ULN * Total Bilirubin ≤ 2 x ULN * Creatinine ≤ 2.0 mg/dL and * Not pregnant or lactating

    Protocol Summary

    The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

    Study Locations

    Location
    Status
    Location
    Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois, United States, 60611
    Status
    Not applicable